Bruce S Thalley

Title: Bruce S Thalley: Innovator in Recombinant Toxin Proteins

Introduction

Bruce S Thalley is a notable inventor based in Madison, WI (US), recognized for his contributions to the field of biotechnology. He holds three patents that focus on recombinant proteins derived from botulinum toxins. His work has significant implications for vaccine development and treatment options for various diseases.

Latest Patents

Thalley's latest patents include innovations such as soluble recombinant botulinum toxin proteins. This invention provides recombinant proteins that are free of significant endotoxin contamination, which are essential for producing vaccines and antitoxins. These proteins are particularly useful in treating humans and animals at risk of intoxication with clostridial toxins. Another significant patent involves a vaccine and antitoxin for the treatment of C. difficile disease. This vaccine is designed to protect recipients from the morbidity and mortality associated with infections, utilizing portions of Toxin A and Toxin B, which may be fusion proteins with non-toxin sequences.

Career Highlights

Throughout his career, Thalley has worked with various companies, including Ophidian Pharmaceuticals, Inc. and Ochidian Pharmaceuticals, Inc. His expertise in recombinant proteins has positioned him as a key figure in the biotechnology sector.

Collaborations

Thalley has collaborated with notable professionals in his field, including John A Kink and Douglas C Stafford. These collaborations have contributed to the advancement of his research and innovations.

Conclusion

Bruce S Thalley is a distinguished inventor whose work in recombinant toxin proteins has the potential to impact vaccine development and treatment strategies significantly. His contributions continue to shape the future of biotechnology.